Comparative Outcomes and Safety of Vedolizumab vs Tumor Necrosis Factor Antagonists for Older Adults With Inflammatory Bowel Diseases.

ABSTRACT:

Importance

Observational comparative effectiveness studies can inform the positioning of biologic therapies for older patients with inflammatory bowel disease (IBD) who are underrepresented in clinical trials.

Objective

To compare the effectiveness and safety of vedolizumab vs tumor necrosis factor (TNF) for older patients with IBD.

Design, setting, and participants

This active comparator, new-user design, comparative effectiveness study was conducted between January 1, 2005, and December 31, 2018, among 754 older patients (aged ≥50 years) with IBD from the Danish National Patient Register. The mean follow-up after treatment initiation took place at 32 to 40 weeks. Statistical analysis was performed from February 1 to April 27, 2022.

Interventions

Treatment wit

SUBMITTER: Singh S 

PROVIDER: S-EPMC9526086 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature